International Health Management Associates, Inc., Schaumburg, IL, USA Varying rates of false-positive results of phenotypic extended-spectrum b-lactamase (ESBL) tests have been reported for different methods in different settings, species and geographic locations. This report describes discrepancies in Escherichia coli genotypic and phenotypic ESBL rates observed in a surveillance study of 29 US hospitals that participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART). The ESBL phenotype was determined with the Clinical and Laboratory Standards Institute confirmatory broth microdilution test using cefotaxime and ceftazidime with and without clavulanate. Genes encoding ESBLs, carbapenemases and plasmidic AmpC b-lactamases were detected using a combination of microarray and multiplex PCR assays. Among 168 molecularly characterized phenotypically ESBL-positive E. coli isolates from intra-abdominal infections, 4.8 % were genotypically negative from 2009 to 2012 and 29.5 % in 2013. Because of the high rate of false-positive phenotypic ESBL results in 2013, the 5-year phenotypic ESBL trend was skewed and showed a statistically significant increase (P<0.05) in ESBL-positive E. coli in the USA, which was not seen using the genotypic ESBL rates. The majority of false-positive phenotypic profiles had ceftazidime MICs of 2 µg ml À1 and a !3 doubling dilution decrease in MIC for only one of the two antimicrobial agents. False-positive ESBL results can adversely impact epidemiological surveillance and patient care (including inappropriate treatment, unnecessary patient isolation and higher costs). Careful evaluation and comparison of phenotypic and genotypic test results can yield the greatest insight, but the most accurate (and faster) detection of ESBL producers is usually based on molecular data.
INTRODUCTION
Extended-spectrum b-lactamase (ESBL) producing Enterobacteriaceae are spreading worldwide, restricting available treatment options even in Escherichia coli, a species generally considered to be broadly susceptible to many antibacterial agents (Dhillon & Clark, 2012; Paterson & Bonomo, 2005) . Knowledge of ESBL status is valuable not only for surveillance of resistance trends, infection control and antimicrobial stewardship, but also most importantly for direct patient care. Serious infections with E. coli are often treated with third-and fourth-generation cephalosporins, but the empiric treatment options for healthcare-associated complicated intra-abdominal infections (IAIs) recommended in the guidelines published by the Infectious Diseases Society of America and the Surgical Infections Society include cefepime and ceftazidime only if ESBL-producing Enterobacteriaceae that can hydrolyse these agents are not commonly seen at the local institution (Endimiani & Paterson, 2007; Solomkin et al., 2010) . In patients with suspected infection caused by an ESBL-producing organism, broad-spectrum agents like carbapenems are often used, thereby increasing the risk of selection of carbapenem-resistant strains and diminishing the effectiveness of these last-resort agents. False-positive phenotypic ESBL tests therefore can result in inappropriate treatment with a potential impact on development of antimicrobial resistance, unnecessary patient isolation and higher costs of care (Wintermans et al., 2013 
METHODS
In 2009-2013, 29 US hospitals enrolled in the Study for Monitoring Antimicrobial Resistance Trends (SMART) collected 2897 E. coli isolates from IAIs. MICs were determined by broth microdilution following CLSI guidelines (Clinical and Laboratory Standards Institute, 2015a, b) . To determine b-lactamase activity, isolates were subjected to the CLSI confirmatory phenotypic ESBL test by broth microdilution, and 230 E. coli isolates tested as phenotypically ESBL positive (7.9 %). Per SMART study protocol, all ertapenem-non-susceptible Enterobacteriaceae and a random selection of 50 % of phenotypically ESBL-positive E. coli, Klebsiella pneumoniae, Klebsiella oxytoca and Proteus mirabilis from each site were to be molecularly characterized. However, sometimes >50 % of ESBL-positive isolates were characterized as part of special regional or species analyses. As a result, 98 % and 96 % of E. coli isolates from IAI collected in the USA were characterized in 2010 and 2011, respectively. Of the 230 E. coli isolates that tested positive for ESBL activity, 168 (73 % overall) were screened for the presence of plasmidmediated b-lactamase genes. Genes encoding ESBLs (bla TEM , bla SHV and bla CTX-M ), carbapenemases (bla KPC , bla NDM , bla IMP , bla VIM and bla OXA-48-like ) and AmpC b-lactamases (bla CMY , bla DHA , bla FOX , bla-MOX , bla ACC , bla MIR and bla ACT ) were detected using a combination of microarray (Check-MDR CT101; Check-Points) and multiplex PCR assays as described previously (Hoban et al., 2012; Kazmierczak et al., . A phenotypic ESBL test result was defined as false-positive if no genes encoding ESBLs were detected in the isolate by molecular methods. Annual rates of genotypically ESBL-positive isolates were estimated using as weights the yearly sampling fractions of phenotypically ESBLpositive isolates (i.e. the proportion of phenotypically ESBL-positive isolates that were molecularly characterized each year). ESBL rates were evaluated for linear trend with the Cochran-Armitage test.
RESULTS AND DISCUSSION
The overall proportion of isolates with a false-positive phenotypic ESBL test result was 11.9 % but varied considerably across years. On average, 4.8 % were false-positive in 2009-2012, similar to the false-positive rate of 4.2 % found in a global comparison of CLSI confirmatory phenotypic and genotypic ESBL tests (Morrissey et al., 2014) ; however, in 2013, the false-positive rate was 29.5 % (Fig. 1) . Correspondingly, the phenotypic and estimated genotypic ESBL rates among E. coli were very similar from 2009 to 2012 but diverged in 2013 (Fig. 2) . Because of the high rate of falsepositives in 2013, the 5-year phenotypic ESBL trend was skewed and showed a statistically significant increase (P<0.05) in ESBL-positive E. coli from IAI in the USA, which was not seen using the estimated genotypic rates and was not reflected in the relatively stable trends in susceptibility to cephalosporins observed over the same time period .
During the study period, a total of 19 isolates collected between 2010 and 2013 were false-positive (Table 1) . Seven of the 13 isolates collected in 2013 were from one hospital, from both medicine and surgery wards and from patients with length of stay both <48 and !48 h at the time of specimen collection. All isolates with a false-positive phenotypic ESBL test result met the CLSI ESBL confirmatory test criteria of MICs for either cefotaxime or ceftazidime of !2 µg ml À1 and a !3 doubling dilution decrease in MIC value for the agent tested in combination with clavulanate. Of the 19 isolates, one isolate produced a Klebsiella pneumoniae carbapenemase (KPC) and was resistant to all tested agents except amikacin. The other 18 isolates exhibited MICs for either cefotaxime or ceftazidime in the susceptible range (cefotaxime, 1 µg ml À1 ; ceftazidime, 4 µg ml
À1
). Of these 18 KPC-negative isolates, 5 (27.8 %) were susceptible to ampicillin-sulbactam (MIC 2 µg ml
) and almost all cephalosporins tested and did not carry any of the tested blactamase genes. The remaining 13 isolates were non-susceptible or resistant to ampicillin-sulbactam (MIC !16 µg ml À1 ), suggesting hyperproduction of the detected TEM-1 (Waltner-Toews et al., 2011) or another b-lactamase lacking ESBL activity such as OXA-1 (Waltner-Toews et al., 2011; Beceiro et al., 2011) -resistance mechanisms known to interfere with phenotypic ESBL testing (Gazin et al., 2012) . Additional reduction or loss of porin production could account for the clavulanate-sensitive cefepimase phenotype observed for some isolates (Beceiro et al., 2011) . However, it cannot explain the elevated cefotaxime MICs observed for others, suggesting the possible presence of undetected b-lactamases in some isolates. Expression levels of TEM-1 and porin proteins were not determined as part of this study.
In summary, compared to genotypic analysis, the confirmatory phenotypic ESBL test can produce false-positive results, which if distributed unevenly across years can lead to spurious trends in ESBL rates. More importantly, false-positive results can have a negative impact on patient management. The CLSI guidelines suggest that laboratories that have not implemented the current cephalosporin and aztreonam breakpoints, which were revised in 2010, should report all confirmed phenotypically ESBL-positive isolates as resistant to penicillins, cephalosporins and aztreonam (Clinical and Laboratory Standards Institute, 2015b) . Furthermore, Livermore et al. (2012) recommended that even when using the new CLSI breakpoints or the lower EUCAST breakpoints, therapy should not be guided by MIC results alone because a low cephalosporin MIC obtained against an ESBL-producing isolate is not a clear predictor of clinical success and because routine susceptibility tests lack the necessary precision to stratify isolates as susceptible/intermediate/resistant across the critical range of 1-4 µg ml
. Rather, they suggested that it would be prudent to take ESBL status into account and avoid treatment with cephalosporins. Kavi et al. (2013) agreed, stressing that knowledge of ESBL status is crucial, especially in patient groups with altered antibiotic pharmacokinetics such as burn or trauma patients, for whom the risk of therapeutic failure against isolates with cephalosporin MICs close to the breakpoint is increased even further. These recommendations mean that patients with a false-positive phenotypic ESBL test result may face more restricted treatment options than necessary and be more likely to receive last-resort agents like carbapenems, underscoring the importance of minimizing such errors. This current study and another report suggest that the phenotypic ESBL test must be interpreted with special caution if cefotaxime or ceftazidime MICs are low (Plateel et al., 2013) and if the combination with clavulanate resulted in a !3 doubling dilution decrease in MIC for only one of the two antimicrobial agents. Additional molecular testing would be especially useful in evaluating such isolates.
Phenotypic tests for ESBL activity remain extremely useful and relevant in clinical laboratories, especially until molecular diagnostic methods become inexpensive and less technically demanding (Livermore et al., 2012; Lupo et al., 2013) . However, false-positive (and false-negative) results can adversely impact patient care and epidemiological surveillance. The greatest amount of information can be gleaned from careful evaluation of both phenotypic and genotypic test results.
